What is he best known for?
The fields of study he is best known for:
Erik De Clercq focuses on Virology, Virus, Stereochemistry, Molecular biology and Biochemistry.
His Virology research includes themes of Reverse transcriptase and Immunology.
His Reverse transcriptase research incorporates themes from Nevirapine and Drug resistance.
His study brings together the fields of Microbiology and Virus.
His research in Stereochemistry intersects with topics in Biological activity, Structure–activity relationship, Chemical synthesis and Enzyme inhibitor.
His studies deal with areas such as Cell culture, Integrase, DNA, Chemokine and CC chemokine receptors as well as Molecular biology.
His most cited work include:
- Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds (1426 citations)
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV). (811 citations)
- Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives (670 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Stereochemistry, Virology, Virus, Biochemistry and Reverse transcriptase.
His Stereochemistry research incorporates elements of Biological activity, Structure–activity relationship and Chemical synthesis.
Erik De Clercq interconnects Bicyclic molecule, Enzyme inhibitor and Reverse-transcriptase inhibitor in the investigation of issues within Chemical synthesis.
Erik De Clercq has researched Virology in several fields, including Molecular biology and In vitro.
Erik De Clercq does research in Virus, focusing on Vesicular stomatitis virus specifically.
His Reverse transcriptase study combines topics from a wide range of disciplines, such as Mutant and Enzyme.
He most often published in these fields:
- Stereochemistry (36.79%)
- Virology (35.50%)
- Virus (19.80%)
What were the highlights of his more recent work (between 2010-2021)?
- Stereochemistry (36.79%)
- Reverse transcriptase (13.61%)
- Virology (35.50%)
In recent papers he was focusing on the following fields of study:
Erik De Clercq mostly deals with Stereochemistry, Reverse transcriptase, Virology, Mutant and Combinatorial chemistry.
As a part of the same scientific study, Erik De Clercq usually deals with the Stereochemistry, concentrating on Structure–activity relationship and frequently concerns with Cell culture.
His Reverse transcriptase study integrates concerns from other disciplines, such as Nevirapine, EC50 and Potency.
The study incorporates disciplines such as Pharmacology and Nucleoside in addition to Virology.
His Mutant research includes elements of Mutation, Molecular biology, Docking and Enzyme.
His research on Virus concerns the broader Immunology.
Between 2010 and 2021, his most popular works were:
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV). (811 citations)
- Approved Antiviral Drugs over the Past 50 Years (524 citations)
- Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends (157 citations)
In his most recent research, the most cited papers focused on:
Erik De Clercq mainly focuses on Stereochemistry, Virology, Reverse transcriptase, Nucleoside Reverse Transcriptase Inhibitor and Diarylpyrimidines.
The various areas that he examines in his Stereochemistry study include Combinatorial chemistry, Delavirdine and Structure–activity relationship.
His studies in Virology integrate themes in fields like Immunology, Pharmacology and Nucleoside.
His Reverse transcriptase research is multidisciplinary, incorporating perspectives in EC50, Biological activity, Docking and Strain.
His Pyrimidine research is multidisciplinary, incorporating elements of Aryl and In vitro.
His Virus research integrates issues from Favipiravir and BCX4430.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
